FDA Panel Unhappy With Novel OA Pain Drug

(MedPage Today) -- An FDA advisory panel voted overwhelmingly--19-1--that a proposed Risk Evaluation and Mitigation Strategy (REMS) program would not ensure a favorable benefit-risk balance for tanezumab, a nerve growth factor inhibitor...